RETRACTABLE TECHNOLOGIES INC — Regulatory Filings 2021

Jun 3, 2021

8-K 1 tm2118314d1_8k.htm FORM 8-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington , D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 28, 2021

Retractable Technologies, Inc.

Field: Rule-Page

Field: /Rule-Page

(Exact name of registrant as specified in its charter)

Texas	001-16465	75-2599762
(State or other jurisdiction	(Commission	(IRS
Employer
of incorporation)	File
Number)	Identification
No.)

511 Lobo Lane, Little Elm, Texas	75068-5295
(Address of principal executive offices)	(Zip
Code)

Registrant's telephone number, including area code (972) 294-1010

None

Field: Rule-Page

Field: /Rule-Page

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	RVP	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1.01 Entry into a Material Definitive Agreement

Effective May 28, 2021, the Company entered into an amendment to the delivery order from the U.S. Department of Health and Human Services which was awarded May 1, 2020. The amendment changes the period of performance end date from May 2021 to March 2022 and reallocates the products ordered to increase shipments of 1mL low dead-space safety syringes. Attached as Exhibit 99.1 is a press release dated June 3, 2021 announcing the amendment.

Item 8.01 Other Events.

On June 1, 2021, the Company issued a press release, a copy of which is attached to this Form 8-K as Exhibit 99.2, announcing its receipt of a notice regarding the extension of a government contract.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Press release announcing amendment to delivery order
99.2	Press release announcing receipt of notice to extend contract

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: June 3, 2021
(Registrant)

BY:
JOHN W. FORT III
VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND CHIEF ACCOUNTING OFFICER

Field: Page; Sequence: 2; Options: Last

Field: /Page